Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) insider Anthony Gibney sold 12,824 shares of Aura Biosciences stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the completion of the transaction, the insider directly owned 265,354 shares in the company, valued at $1,703,572.68. This represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Aura Biosciences Trading Up 0.5%
NASDAQ AURA opened at $6.31 on Thursday. The firm’s fifty day simple moving average is $7.21 and its two-hundred day simple moving average is $6.34. Aura Biosciences, Inc. has a 12-month low of $4.73 and a 12-month high of $9.53. The firm has a market capitalization of $652.39 million, a P/E ratio of -3.63 and a beta of 0.39.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). As a group, sell-side analysts predict that Aura Biosciences, Inc. will post -1.73 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of research firms recently issued reports on AURA. Wall Street Zen upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. HC Wainwright boosted their target price on shares of Aura Biosciences from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Finally, Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a research report on Tuesday, May 12th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.50.
Get Our Latest Stock Analysis on AURA
About Aura Biosciences
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Featured Articles
- Five stocks we like better than Aura Biosciences
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
